São Paulo, July, 2026 – Eurofarma announces the launch of XCOPRI® (cenobamate) in the Brazilian market, an innovative therapy indicated for the treatment of drug-resistant epilepsy in adults. As the first cenobamate-based medicine approved in Brazil, XCOPRI® expands treatment options for patients who continue to experience persistent seizures despite multiple therapeutic interventions. Approved by the Brazilian Health Regulatory Agency (Anvisa) in March 2026 and with pricing established by the Drug Market Regulation Chamber (CMED) in July, XCOPRI® is expected to be available in pharmacies nationwide starting in August 2026 in 12.5 mg, 50 mg, 100 mg, and 200 mg presentations.

The launch reinforces Eurofarma’s strategy of translating innovation into meaningful healthcare solutions and marks a new chapter in strengthening the company’s central nervous system portfolio. Already commercialized by the company since May in other Latin American countries, including Chile and Peru, the medicine results from a strategic licensing partnership with South Korea-based SK Biopharmaceuticals, the developer of the molecule, expanding regional access to therapies that address unmet medical needs.

"Our commitment to innovation ultimately reaches patients, helping transform their daily lives. Treatment with cenobamate can significantly reduce epileptic seizures in people with drug-resistant epilepsy, providing meaningful benefits in terms of quality of life and independence. Patients who previously had no access to innovative medicines like this – or who relied on exceptional importation programs – will now have a new therapeutic option available in Brazil" said Renata Campos, CEO of Eurofarma Brazil.

Innovation with Exceptional Efficacy
Cenobamate stands out for its unique and differentiated mechanism of action, combining sodium channel modulation with enhancement of GABA-mediated inhibitory neurotransmission (gamma-aminobutyric acid), both through mechanisms unprecedented among currently available anti-seizure medications. As a result, pivotal clinical trials demonstrated an unprecedented efficacy profile in the treatment of drug-resistant focal epilepsy. 

When used as adjunctive therapy (in combination with another treatment), patients receiving 400 mg/day achieved a median 65% reduction in focal seizure frequency during the maintenance phase¹, while the 200 mg/day dose resulted in a median reduction of 55.6%², with consistent findings across both studies.^1,2 Notably, approximately one in five patients (21%¹ and 28.3%²) achieved complete seizure freedom—a clinical outcome rarely observed with other available pharmacological therapies. By comparison, after three lines of treatment with conventional anti-seizure medications, only 4% of patients achieve the same result³, highlighting cenobamate’s transformative potential in epilepsy management. 

Recent real-world evidence further supports these findings. In a 2025 study, 79.6% of patients achieved a ≥50% reduction in seizure frequency after one year of treatment with cenobamate, while 36.6% became seizure-free. These outcomes remained strong after two years, with 80% achieving a ≥50% reduction and 30.9% maintaining seizure freedom. Treatment adherence was high, with a significant reduction in the number and dosage of concomitant anti-seizure medications, indicating a simplification of the therapeutic regimen. These results reinforce the sustained efficacy and favorable adherence profile of cenobamate in real-world clinical practice, particularly among patients with difficult-to-control epilepsy.⁴ 

Epilepsy: A Public Health Challenge
Epilepsy is one of the most prevalent chronic neurological disorders worldwide and remains a major public health challenge. In Brazil, it is estimated that approximately 1% to 2% of the population lives with epilepsy, representing roughly two to three million people directly or indirectly affected by the condition.⁵ Across Latin America and the Caribbean, the situation is similarly challenging. The region is home to more than six million people with active epilepsy, and over 60% of patients do not receive adequate treatment due to barriers such as delayed diagnosis, limited access to specialists, and restricted availability of innovative therapies.^5-7 As a result, epilepsy continues to be associated with high levels of disability, social stigma, and reduced quality of life.

The arrival of new therapeutic options in the Brazilian and Latin American markets represents a significant advance for both healthcare systems and the millions of people who live with the burden of epilepsy every day.

References
1. Krauss, G. L. et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 19, 38–48 (2020).
2. Chung, S. S. et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology 94, e2311–e2322 (2020).
3. Chen, Z., Brodie, M. J., Liew, D. & Kwan, P. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurol. 75, 279–286 (2018).
4. Sánchez-Caro JM, Hariramani Ramchandani R, Maestro Saiz I, Rodríguez Uranga JJ. Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: A real-world retrospective study in Spain. Epilepsia. 2025 Nov 12.
5. Alva-Díaz, C. et al. Prevalence and incidence of epilepsy in Latin America and the Caribbean: a systematic review and meta-analysis of population-based studies. Epilepsia. 62, 984–996 (2021).
6. Bruno, E. et al. Epilepsy and neurocysticercosis in Latin America: a systematic review and meta-analysis. PLoS Negl Trop Dis. 7, e2480 (2013).
7. Pacheco-Barrios, K. et al. Burden of epilepsy in Latin America and the Caribbean: a trend analysis of the Global Burden of Disease Study 1990–2019. Lancet Reg Health Am. 8, 100167 (2022).

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector with the production and commercialization of products and services aimed at improving people’s quality of life. Focused on generating shared value, the company covers the main pharmaceutical segments, including prescription drugs, generics, hospital products, oncology, over-the-counter medicines, personal care, and animal health, in addition to providing third-party manufacturing services.

With broad therapeutic coverage, its portfolio comprises more than 4,000 SKUs, serving virtually all medical specialties. A leader in prescription drugs in Brazil—where it also holds second place in generics—Eurofarma is present in 24 countries, with full coverage across Latin America and a leading position in the region’s retail market. It also operates in the United States and Africa, employing more than 13,000 people and maintaining 11 manufacturing facilities, with a total of 630 million units produced in 2025. In the same year, the company invested more than BRL 700 million in innovation projects and achieved net revenue exceeding BRL 12 billion.

Press Information
G&A Relações Públicas

Iza França -11 97644-4496 - iza.franca@gaspar.com.br
Guilherme Gaspar -11 98285-6000 - guilherme@gaspar.com.br
Murillo Israel – murillo.israel@gaspar.com.br
Anne Ikehara - anne.ikehara@gaspar.com.br